MyFinsight
Home
Blog
About
Proceeds from the
exercise of share options
$330K
(-89.16%↓ Y/Y)
Net cash provided by
financing activities
$330K
(-97.92%↓ Y/Y)
Effect of foreign
exchange rates on cash,...
$123K
(21.78%↑ Y/Y)
Net decrease in
cash, cash...
-$176,583K
(-88.71%↓ Y/Y)
Canceled cashflow
$453K
Share-based compensation
expense
$10,733K
(-3.73%↓ Y/Y)
Accrued expenses and
other current...
$5,199K
(164.54%↑ Y/Y)
Accounts payable
$1,568K
(188.29%↑ Y/Y)
Amortization of right-of-use
assets
$1,511K
(-42.33%↓ Y/Y)
Prepaid expenses
-$1,104K
(61.18%↑ Y/Y)
Depreciation of property and
equipment
$858K
(-50.69%↓ Y/Y)
Net cash used in
investing activities
-$123,454K
(-26111.04%↓ Y/Y)
Net cash used in
operating activities
-$53,582K
(50.87%↑ Y/Y)
Canceled cashflow
$20,973K
Purchases of marketable
securities
$122,570K
Purchases of property and
equipment
$884K
(87.69%↑ Y/Y)
Net loss
-$69,355K
(28.75%↑ Y/Y)
Operating lease
liabilities
-$2,140K
(42.05%↑ Y/Y)
Deferred revenue
-$1,385K
(91.48%↑ Y/Y)
Accounts receivable
$888K
(355.38%↑ Y/Y)
Other assets
$722K
(791.36%↑ Y/Y)
Accretion of investment
premium
$65K
Back
Back
Cash Flow
Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. (WVE)
source: myfinsight.com